不同心力衰竭患者使用重组人脑利钠肽的疗效及安全性分析  

Efficacy and safety of recombinant human brain natriuretic peptide in different heart failure patients

作　　者：郭未艳[1] 王园姬 段石顽 李勇卫 吕娟 李亚美 GUO Weiyan;WANG Yuanji;DUAN Shiwan;LI Yongwei;LYU Juan;LI Yamei(Department of Pharmacy,Xi’an NO.1 Hospital,Xi’an 710002,Shaanxi Province,China)

机构地区：[1]西安市第一医院药剂科,陕西西安710002

出　　处：《世界临床药物》2022年第1期39-44,共6页World Clinical Drug

基　　金：2017西安市卫生局科技计划项目(J201701004)。

摘　　要：目的分析重组人脑利钠肽(recombinant human brain natriuretic peptide,rh-BNP)对不同心力衰竭患者的临床疗效。方法采用回顾性分析法,对2018年1月至2018年12月期间在西安市第一医院治疗的心力衰竭患者,分别采用美国纽约心脏病协会(New York Heart Association,NYHA)和凯氏(Killip)心功能进行分级,并对使用rh-BNP前后N末端脑钠肽前体(N-terminal probrain natriuretic peptide,NT-proBNP)、高敏肌钙蛋白(high-sensitivity troponin T,hs-cTnT)、肌酸激酶同工酶(creatine kinase isoenzyme,CK-MB)、肌红蛋白(myoglobin,MYO)等生物标记物水平进行分析,记录不良反应发生情况,分析患者治疗状况。结果NYHA和Killip心功能分级心力衰竭患者使用rh-BNP后的NT-proBNP、hs-cTnT、CK-MB、MYO水平均有显著降低(P<0.05)。两组治疗后结果比较,Killip心功能分级心力衰竭患者的NT-proBNP更低(P<0.05);NYHA功能分级心力衰竭患者的hs-cTnT、CK-MB、MYO水平更低(P<0.05)。两组患者不良反应发生率及治疗有效性无显著性差异(P>0.05)。结论rh-BNP对于NYHA和Killip心功能分级心力衰竭患者同样安全有效,值得临床推广使用。Objective To analyze the clinical efficacy of recombinant human brain Natriuretic peptide(RH-BNP)in patients with different heart failure,in order to provide more evidence for the clinical application of Rh-BNP.Methods Using retrospective analysis,for patients with heart failure treated in Xi'an First Hospital from January 2018 to December 2018,the New York Heart Association(NYHA)and Kay were used.Killip's cardiac function was graded,and N-terminal probrain natriuretic peptide(NT-proBNP),high-sensitivity troponin T(hs-cTnT)before and after the use of (rh-BNP),creatine kinase isoenzyme(CK-MB),myoglobin(MYO)and other biomarkers level to analyze,record the occurrence of adverse reactions,and analyze the patient's treatment status.Results The levels of NT-proBNP,hs-cTnT,CK-MB,and MYO in patients with NYHA and Killip cardiac function classification heart failure using rh-BNP were significantly reduced(P<0.05).Comparing the results of treatment between the two groups,NT-proBNP was lower in patients with Killip cardiac function classification heart failure(P<0.05);the levels of hs-cTnT,CK-MB and MYO in patients with NYHA function classification heart failure were lower(P<0.05).There was no significant difference in the incidence of adverse reactions and the effectiveness of treatment between the two groups(P>0.05).Conclusion rh-BNP is also safe and effective for NYHA and Killip cardiac function grading patients with heart failure,and it is worthy of clinical application.

关 键 词：重组人脑利钠肽 心力衰竭 美国纽约心脏病协会分级 凯氏心分级 

分 类 号：R54[医药卫生—心血管疾病]